Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488275 | 0.89 | SMYD3 (0.57) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL9070470 | 0.84 | CA12 (0.56) | ALDH1A1L3MBTL1RAB9ANPC1CA12 | |
| SCHEMBL1299987 | 0.84 | ALOX15 (0.56) | ALDH1A1L3MBTL1CA12CA1CA2 | |
| SCHEMBL1688436 | 0.83 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL1285418 | 0.83 | MAPT (0.54) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL5513069 | 0.82 | NUDT1 (0.48) | ALDH1A1L3MBTL1KDM4EMAPTTSHR | |
| SCHEMBL24478621 | 0.82 | LMNA (0.50) | ALDH1A1L3MBTL1RAB9ANPC1KDM4E | |
| SCHEMBL1680503 | 0.81 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL16621161 | 0.81 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 | |
| SCHEMBL23202895 | 0.81 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| EP-1615636-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089366-A1 | BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN, INC. (JP) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | ANDO KAZUO (JP) | 2004-10-14 | — | — | US | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | RET, ABL1, PRKACA | ALDH1A1 3221/4885L3MBTL1 966/4885RAB9A 578/4885 |
| US-20040204409-A1 | Bicyclic compounds as NR2B receptor antagonists | GRIN1, GRIN2B, GRIN2A | ALDH1A1 1871/4885L3MBTL1 1675/4885RAB9A 4106/4885 |
| US-20080234267-A1 | Compounds and Methods of Treatment | RET, ABL1, PRKACA | ALDH1A1 3221/4885L3MBTL1 966/4885RAB9A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.